�㽭ʡ�����еڶ�����ҽԺ

��ժҪ�� ��ʮ�������������߼���������ѧ�ķ�չ�����SLE���߲�����ƻ���ذе�������������ҩ��ȡ�����ش��չ���Ա�������Ϊ��־�������������ҩ��ΪSLE�����ƿ������µ�;����Ŀǰ�н�20��SLE��������ҩ���ڽ����ٴ�ǰ�ڻ��ٴ��о������������ð�λ�IJ�ͬ��Ҫ��Ϊ����7�ࣺBϸ�������԰е�ҩ�Tϸ��/���̼����������԰е�ҩ�ϸ���������Ƽ�����Ȼ���߰�λ������ԭ��ϸ�������������Ƽ��Լ�����ϸ����������-1/����ϸ����������CC����2���Ƽ���N-�������װ���������е�ҩ� ���ؼ��ʡ� ����Ǵ�,ϵͳ�ԣ� ���壬����¡�� ����

SHI Ping-rong. Department of Dermatology, Second People's Hospital of Wenling, Wenling 317502, Zhejiang, China ��Abstract�� With the development of immunology and molecular biology, great advances have been made in biological therapies targeted at the immunopathological mechanisms or directed against some targets in systemic lupus erythematosus ��SLE�� in the past decade. These biological agents, with belimumab as a representative, have offered a new approach to the treatment of SLE. At present, there are nearly 20 targeted drugs for SLE that undergo preclinical research or clinical trials. According to the difference in action targets, they are mainly divided into seven categories: B-cell-targeted drugs, T-cell/costimulatory molecule-targeted drugs, cytokine inhibitors, innate immunity-targeted drugs, tolerogens, inhibitors of cell surface receptors, and other targeted agents including monocyte chemoattractant protein 1/monocyte chemoattractant CC chemokine ligand 2 inhibitors, N-acetyl cysteine, etc. ��Key words�� Lupus erythematosus, systemic; Antibodies, monoclonal; Therapy